BR112022025900A2 - Formulações tópicas de (1s)-1-fenil-2-piridin-2-iletanamina - Google Patents

Formulações tópicas de (1s)-1-fenil-2-piridin-2-iletanamina

Info

Publication number
BR112022025900A2
BR112022025900A2 BR112022025900A BR112022025900A BR112022025900A2 BR 112022025900 A2 BR112022025900 A2 BR 112022025900A2 BR 112022025900 A BR112022025900 A BR 112022025900A BR 112022025900 A BR112022025900 A BR 112022025900A BR 112022025900 A2 BR112022025900 A2 BR 112022025900A2
Authority
BR
Brazil
Prior art keywords
phenyl
yletanamine
pyridin
topical formulations
pharmaceutically acceptable
Prior art date
Application number
BR112022025900A
Other languages
English (en)
Inventor
Berman Robert
Kumar Rajesh
M Conway Charles
K Donohue Mary
Kumar Reka Ajaya
Original Assignee
Biohaven Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biohaven Therapeutics Ltd filed Critical Biohaven Therapeutics Ltd
Publication of BR112022025900A2 publication Critical patent/BR112022025900A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)

Abstract

FORMULAÇÕES TÓPICAS DE (1S)-1-FENIL-2-PIRIDIN2-ILETANAMINA. A presente invenção fornece uma formulação farmacêutica incluindo (1S)-1-fenil-2-piridin-2-iletanamina, um sal farmaceuticamente aceitável do mesmo, um solvato do mesmo ou um profármaco do mesmo; e um carreador tópico farmaceuticamente aceitável. Também é fornecido um método para o tratamento de dor neuropática pela administração, a um paciente com necessidade de tal tratamento, de uma quantidade terapeuticamente eficaz da formulação farmacêutica.
BR112022025900A 2020-06-23 2021-06-23 Formulações tópicas de (1s)-1-fenil-2-piridin-2-iletanamina BR112022025900A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063043075P 2020-06-23 2020-06-23
PCT/US2021/038564 WO2021262779A1 (en) 2020-06-23 2021-06-23 Topical formulations of (1s)-1-phenyl-2-pyridin-2-ylethanamine

Publications (1)

Publication Number Publication Date
BR112022025900A2 true BR112022025900A2 (pt) 2023-01-10

Family

ID=79281832

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022025900A BR112022025900A2 (pt) 2020-06-23 2021-06-23 Formulações tópicas de (1s)-1-fenil-2-piridin-2-iletanamina

Country Status (11)

Country Link
US (1) US20230190719A1 (pt)
EP (1) EP4168116A1 (pt)
JP (1) JP2023531918A (pt)
KR (1) KR20230026449A (pt)
CN (1) CN115836052A (pt)
AU (1) AU2021297823A1 (pt)
BR (1) BR112022025900A2 (pt)
CA (1) CA3187140A1 (pt)
IL (1) IL299308A (pt)
MX (1) MX2022016183A (pt)
WO (1) WO2021262779A1 (pt)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG47948A1 (en) * 1992-04-03 1998-04-17 Astra Ab Compounds for the treatment of neurodegenerative disorders
US20040082543A1 (en) * 2002-10-29 2004-04-29 Pharmacia Corporation Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain
ES2733344T3 (es) * 2013-11-05 2019-11-28 Astrazeneca Ab Profármacos antagonistas de NMDA
US11358935B2 (en) * 2016-11-28 2022-06-14 Biohaven Pharmaceutical Holding Company Ltd. Prodrugs of lanicemine and their method of use
US20210251969A1 (en) * 2018-08-20 2021-08-19 Yale University Combination Therapy for Treating or Preventing Depression or Other Mood Diseases

Also Published As

Publication number Publication date
EP4168116A1 (en) 2023-04-26
US20230190719A1 (en) 2023-06-22
KR20230026449A (ko) 2023-02-24
JP2023531918A (ja) 2023-07-26
CN115836052A (zh) 2023-03-21
WO2021262779A1 (en) 2021-12-30
IL299308A (en) 2023-02-01
MX2022016183A (es) 2023-02-13
CA3187140A1 (en) 2021-12-30
AU2021297823A1 (en) 2023-02-16

Similar Documents

Publication Publication Date Title
BRPI0707235B1 (pt) formulação de fentanil sublingual sem propelente, e, dispositivo de dose unitária para administração sublingual de uma formulação de fentanil sublingual
EA201590166A1 (ru) Комбинированная терапия для лечения рассеянного склероза
MX2020008258A (es) Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos.
BR112012029959A2 (pt) compostos de carbamato de mentila como ativos para clareamento de pele e/ou cabelo
BR0307898A (pt) Formulações de droga antibiótica oftálmica contendo um composto de ciclodextrina e cloreto de cetil piridìnio
BR0110030A (pt) Método para tratamento de dor através da administração periférica de uma neurotoxina
MX2021005651A (es) Combinacion farmaceutica para el tratamiento contra el cancer.
MX2019012884A (es) Terapia de combinacion.
BR112014015482A8 (pt) compostos carbamato de fenila para uso no alívio ou tratamento de dor e dor neuropática
BRPI0607536A2 (pt) tratamento de dor
EA200870469A1 (ru) Новые, содержащие нимесулид, фармацевтические композиции с низкой дозой, их получение и применение
CL2023000881A1 (es) Compuestos y su uso en el tratamiento del cáncer
RU2014142038A (ru) Короткие антимикробные липопептиды
MX2022015554A (es) Moduladores de molecula peque?a de interleucina 17 (il-17).
EA202190544A1 (ru) Применение распадающихся в полости рта таблеток рилузола для лечения заболеваний
BR0206954A (pt) Processo de terapia para câncer
EA201990419A1 (ru) Слаборастворимый комплекс или его сольват, фармацевтическая композиция и их применение
EA201101622A1 (ru) Пептидная фармацевтическая композиция, средство на ее основе для лечения гастродуоденальных заболеваний, вызываемых helicobacter pylori, и способ его использования
BR112022025900A2 (pt) Formulações tópicas de (1s)-1-fenil-2-piridin-2-iletanamina
MX2022003845A (es) Tratamientos cognitivos medicinales.
BR112023023702A2 (pt) Métodos de tratamento da cistite intersticial/síndrome da dor na bexiga
BR112014001503A2 (pt) composições farmacêuticas compreendendo 4-bromo-n-(imidazolidin-2-ilideno)-1h-benzimidazol-5-amina para o tratamento de doenças de pele
ES2971823T3 (es) Mejora de las acciones antibacterianas de un antibiótico depsipeptídico mediante cantidades sinérgicas de ácido bórico
BR112018072164A2 (pt) composição farmacêutica, método para tratamento e/ou prevenção de uma doença de pele de um paciente e/ou para alívio dos sintomas da mesma, e, uso cosmético de uma composição
BR112022010733A2 (pt) Métodos para tratar dor